Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial
Paul Kim(Profectus Biosciences (United States)), Paul M. Garofolo(Profectus Biosciences (United States)), Robert W. McKee(Profectus Biosciences (United States)), Taylor J.R. Penke(University of North Carolina at Chapel Hill), Ana M. Sánchez(Profectus Biosciences (United States)), Lana J. McMillan(Profectus Biosciences (United States)), William L. Slone(West Virginia University), J. Kime(Profectus Biosciences (United States)), Cameron J. Prybol(Profectus Biosciences (United States)), Nicholas R. Conley(Profectus Biosciences (United States)), Hannah H. Tuson(Profectus Biosciences (United States))
Cited by 83
Related Papers
Survivin and molecular pathogenesis of colorectal cancer
|The Lancet|2003|322
Inhibition of melanoma tumor growth <i>in vivo</i> by survivin targeting
|Proceedings of the National Academy of Sciences|2001|285
<i>In Vivo</i> Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials
|mBio|2020|220
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53
|Journal of Clinical Investigation|2001|194
Autophagy Regulation of Metabolism Is Required for CD8+ T Cell Anti-tumor Immunity
|Cell Reports|2019|182